• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

    3/17/25 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email

    - Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested

    - Favorable safety profile, with no safety concerns

    - Data will support planned regulatory submission for povorcitinib in hidradenitis suppurativa (HS) worldwide

    - Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET

    Incyte (NASDAQ:INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).

    Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count. The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was:

    STOP-HS1:

    45 mg: 40.2% vs. 29.7% [P=0.024]

    75 mg: 40.6% vs 29.7% [P=0.022]

    STOP-HS2:

     

    45 mg: 42.3% vs. 28.6% [P=0.004]

    75 mg: 42.3% vs. 28.6% [P=0.003]

    Within a predefined subgroup of patients previously exposed to biologics, povorcitinib demonstrated greater differential efficacy (HiSCR50) when compared to placebo (nominal P-values):

    STOP-HS1:

    45 mg: 34.2% vs. 21.9% [P=0.096]

    75 mg: 37.8% vs. 21.9% [P=0.037]

    STOP-HS2:

     

    45 mg: 45.0% vs. 19.5% [P=0.001]

    75 mg: 40.0% vs. 19.5% [P=0.005]

    In addition, at Week 12, patients treated with povorcitinib achieved deep levels of clinical response with a greater proportion achieving HiSCR75, reduction in flares, >3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30. Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.

    The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated.

    "Hidradenitis suppurativa is a challenging and debilitating condition without a cure. Given the limitations of current HS treatments and its impact on patients' daily lives, there is a critical need for new, well tolerated and effective therapies that provide a rapid reduction in the signs and symptoms of HS, in particular, pain," said Steven Stein, M.D., Chief Medical Officer, Incyte. "The positive Phase 3 data highlights the potential of povorcitinib as an effective oral treatment option for people living with HS."

    These data support the planned regulatory submission of povorcitinib for the treatment of HS worldwide. Additionally, data from both STOP-HS studies will be submitted for presentation at upcoming scientific meetings.

    About STOP-HS

    The STOP-HS clinical trial program includes two Phase 3 studies, STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836), evaluating the efficacy and safety of povorcitinib (INCB54707) in adult patients with moderate to severe HS. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up.

    The studies have each enrolled approximately 600 patients (age ≥18 years) diagnosed with moderate to severe HS for at least three months prior to the screening visit and meet certain criteria: total AN count of ≥5, lesions in at least two distinct anatomical areas, and have a documented history of inadequate response to at least a three-month course of at least one conventional systemic therapy (oral antibiotic or biologic drug) for HS, or have demonstrated intolerance to, or have a contraindication to, such conventional systemic therapies.

    The primary endpoint for both studies is the proportion of patients who achieve HiSCR50, defined as at least a 50% reduction from baseline in the total AN count at Week 12, with no increase from baseline in abscess or draining tunnel count. Key secondary endpoints include the proportion of patients achieving a 75% reduction in AN count with no increase from baseline in abscess or draining tunnel count (HiSCR75) at Week 12, the proportion of patients experiencing at least one flare-up over 12 weeks, the proportion of patients with a >3-point decrease in the Skin Pain NRS score among those with a baseline score of ≥3, and the proportion of patients achieving a 30% reduction and at least 1-unit reduction from baseline in Skin Pain NRS at Week 12. The studies also evaluate the frequency and severity of adverse events during the study.

    For more information on the STOP HS studies, please visit https://clinicaltrials.gov/study/NCT05620823 and https://clinicaltrials.gov/study/NCT05620836.

    Incyte Conference Call and Webcast

    Incyte will hold a conference call and webcast today at 8:00 a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or +1 201-389-0864 for international callers. When prompted, provide the conference identification number: 13752265. If you are unable to participate, a replay of the conference call will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415. To access the replay, you will need the conference identification number: 13752265.

    The conference call will also be webcast live and can be accessed at investor.incyte.com.

    About Hidradenitis Suppurativa

    Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses that can lead to irreversible tissue destruction and scarring.i,ii Over-activity of the JAK/STAT signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS.iii More than 150,000 patients in the U.S. are estimated to have moderate to severe HS.iv Given the debilitating nature of the condition, it can have a profoundly negative effect on patients' quality of life.v

    About Povorcitinib

    Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as Phase 2 trials for asthma and chronic spontaneous urticaria (CSU).

    Incyte Forward-Looking Statements

    Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the regulatory submissions for povorcitinib worldwide; the submission of STOP-HS data for presentation at upcoming scientific meetings; the potential of povorcitinib to be an effective and well-tolerated treatment option for HS patients; and further clinical studies of povorcitinib, contain predictions, estimates and other forward-looking statements.

    These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other regulatory authorities; the efficacy or safety of Incyte's products; the acceptance of Incyte's products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.

    1

    National Center for Advancing Translational Science Genetic and Rare Diseases Information Center. Hidradenitis suppurativa. https://rarediseases.info.nih.gov/diseases/6658/hidradenitis-suppurativa. Accessed February 7, 2024.

    2

    Kirby, JS et al. (2024). Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. Journal of the American Academy of Dermatology, Volume 90, Issue 3, 521-529.

    3

    Maronese, CA et al (2024). Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Review of Clinical Immunology, Volume 20, Issue 5, 525-545.

    4

    McMillan, K. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. Am J Epidemiol. 2014 Jun 15;179(12):1477-83. doi: 10.1093/aje/kwu078. Epub 2014 May 8.

    5

    Sabat, R et al (2025). Hidradenitis suppurativa. The Lancet, Volume 405, Issue 10476, 420-438.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250317947508/en/

    Media

    [email protected]



    Investors

    [email protected]

    Get the next $INCY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    8/6/2025$89.00Equal Weight → Overweight
    Wells Fargo
    8/1/2025$90.00Overweight
    Barclays
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    More analyst ratings

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incyte to Present at Upcoming Investor Conferences

    Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT) Well Fargo Healthcare Conference on Thursday, September 4, 2025 at 8:45 am (EDT) Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 10:00 am (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs.

    8/19/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

    - Company initiates search for successor and reaffirms full year financial guidance Incyte (NASDAQ:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and Chief Financial Officer (CFO) to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain with the Company until then to support a smooth transition. The Company has initiated the process of appointing a successor. "Since joining Incyte in 2019, Christiana has been an invaluable part of the leadership team. I would like to take this opportunity to thank Christiana for her many contributions, and wish her well in her future endeavors," said Bill Meury, Pres

    8/5/25 4:05:00 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

    MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) in Latin America. Under the terms of the amended agreement Incyte will be responsible for the development, manufacture and supply to Knight of retifanlimab and axatilimab, and Knight will be responsible for

    8/4/25 4:30:00 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $INCY
    SEC Filings

    View All

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

    9/28/21 5:20:01 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

    9/23/21 5:11:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for OPZELURA issued to INCYTE CORP

    Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    9/22/21 11:16:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Incyte from Equal Weight to Overweight and set a new price target of $89.00

    8/6/25 7:56:54 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Barclays initiated coverage on Incyte with a new price target

    Barclays initiated coverage of Incyte with a rating of Overweight and set a new price target of $90.00

    8/1/25 8:13:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte upgraded by Stifel with a new price target

    Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00

    6/16/25 7:42:04 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by Incyte Corp.

    144 - INCYTE CORP (0000879169) (Subject)

    8/12/25 4:21:26 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Corp. filed SEC Form 8-K: Leadership Update

    8-K - INCYTE CORP (0000879169) (Filer)

    8/7/25 9:08:14 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Incyte Corp.

    10-Q - INCYTE CORP (0000879169) (Filer)

    7/29/25 4:01:59 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & General Counsel Denton Sheila A. exercised 277 shares at a strike of $64.25 and sold $24,046 worth of shares (277 units at $86.81) (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    8/19/25 4:13:11 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & General Counsel Denton Sheila A. exercised 598 shares at a strike of $58.06 and sold $45,310 worth of shares (598 units at $75.77) (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    8/6/25 4:03:10 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    New insider Mayes Patrick A claimed ownership of 67,388 shares (SEC Form 3)

    3 - INCYTE CORP (0000879169) (Issuer)

    8/5/25 4:03:49 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    View All

    Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

    - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

    6/26/25 7:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

    Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr

    6/12/23 4:01:00 PM ET
    $GLPG
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Incyte Names New Member to Its Board of Directors

    Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company

    10/4/22 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Financials

    Live finance-specific insights

    View All

    Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

    – Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-

    7/29/25 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte to Report Second Quarter Financial Results

    Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

    7/10/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

    Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

    6/15/25 3:15:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Incyte Corp.

    SC 13G - INCYTE CORP (0000879169) (Subject)

    10/17/24 9:39:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by Incyte Corp.

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    6/14/24 6:23:05 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    5/13/24 6:06:33 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care